Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

63P - Role of EGFR-targeted therapy in the treatment of advanced and metastatic cervical cancers


06 Mar 2023


Cocktail & Poster Display session


Abhishek Krishna


Annals of Oncology (2023) 8 (1suppl_2): 100896-100896. 10.1016/esmoop/esmoop100896


A. Krishna1, A. Ms2, S. Banerjee2, J. Sunny Kilikunnel2, C. Srinivas2, D. Lobo2

Author affiliations

  • 1 Radiation Oncology, Kasturba Medical College, 575003 - Mangalore/IN
  • 2 Radiation Oncology, Kasturba Medical College, 575001 - Mangalore/IN


This content is available to ESMO members and event participants.

Abstract 63P


The treatment of choice for locally advanced cervical cancer is radiation therapy combined with concomitant chemotherapy using platinum complexes. 30 to 50% of patients with locally advanced stage will have a recurrence. The overall outcome for such recurrent cervical cancer is bleak, and treating such individuals remains a challenge. Due to chemotherapy's limited effectiveness and toxicity, targeted therapy agents have been tried to improve the outcomes. There are only a handful of studies wherein Gefitinib has been used to treat carcinoma of the cervix. This research looked at gefitinib’s role in treating recurrent and metastatic cervical cancer.


Patients diagnosed with metastatic cervical cancer or those who developed any recurrence post-chemoradiation or distant metastases either upfront or post-chemoradiation were eligible to be enrolled in the study. The patients were administered with gefitinib at 250 mg per day after verification of their blood parameters. Gefitinib was continued until the patient withdrew consent or the disease progressed. RECIST criteria was used to evaluate the patient's response to therapy. Toxicities were assessed with CTCAE criteria.


Thirty patients with a median age of 58.5 years were included. Majority of the patients had FIGO stage IIIB disease at their initial presentation. Twenty-seven patients received salvage chemotherapy prior to Gefitinib. The median follow-up time was seen to be 6 months (3 -15 months). Two patients (7%) had a complete clinical response, 7 patients in the study (23%) was seen to have a partial response, 5 patients out of the 30 patients (17%) showed a stable disease whereas 16 patients were seen to have progressive disease (53%). The disease control rate, signified by patients with complete, partial response, and stable disease was 47%. The median PFS was noted to be 4.5 months and the 1-year PFS was 20%. None of the individuals experienced toxicity of grade 3 or higher. All toxicities were managed conservatively.


The EGF receptor, expressed by different types of cancers has been discovered as a promising anti-cancer target. Given the positive results and low toxicity, gefitinib could be a promising treatment approach for individuals with advanced cervical cancers.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.